MetaVia Completes Dose Titration in Phase 1 Trial for Obesity Drug DA-1726
Event summary
- MetaVia completed dose titration in Phase 1 Part 3 trial for DA-1726, with all patients reaching target doses of 48 mg and 64 mg.
- The study evaluated one-step and two-step titration strategies to optimize tolerability and achieve higher doses.
- Topline data from the trial is expected in Q4 2026.
- DA-1726 demonstrated a 9.1% mean weight loss at the 48 mg dose in an earlier Phase 1 MAD study.
The big picture
MetaVia's completion of dose titration in the Phase 1 trial for DA-1726 marks a critical step in developing a potential best-in-class obesity treatment. The dual GLP-1/glucagon mechanism of DA-1726 aims to address unmet needs in weight loss and metabolic health, positioning it against leading therapies like Wegovy and Zepbound. The upcoming topline data will be pivotal in assessing the drug's competitive edge in a rapidly evolving obesity treatment landscape.
What we're watching
- Competitive Advantage
- Whether MetaVia's efficient titration strategy can differentiate DA-1726 from existing obesity therapies.
- Clinical Efficacy
- The pace at which topline data will confirm the weight loss and metabolic benefits of DA-1726.
- Market Positioning
- How MetaVia positions DA-1726 against established GLP-1 agonists like semaglutide and tirzepatide.
Related topics